Introduction
Minocycline is a second-generation tetracycline antibiotic with anti-inflammatory effects. 1 Its mechanisms of action in the central nervous system (CNS) include suppression of microglia and T cell activation 2 as well as reduced proinflammatory cytokine release. 3 Activated microglia and interleukin release have been implicated in epileptogenesis and ictogenesis in animal models, 4 however experimental evidence is more convincing for cases of ictogenesis rather than epileptogenesis. We present a case suffering from drug resistant symptomatic focal epilepsy with frequent seizures who achieved almost complete seizure freedom after treatment with minocycline.
Case report
A 53 years-old retired office employee was seen in the outpatient clinic of our epilepsy centre for the first time in 2006. In 1998 he had undergone resection of an astrocytoma WHO II8 in the right supplementary motor area with residual mild left-sided hemiparesis and reduced word fluency due to right-hemispheric language dominance. Additionally, a melanoma at the right shoulder was diagnosed and resected in 2006. Minocycline, a tetracycline family antibiotic, is known to inhibit microglial activation and proinflammatory cytokine release in animal models. Experimental data show that these immune processes may play a role in epilepto-and ictogenesis. We present the case of a patient with marked reduction in seizure frequency during minocycline therapy with severe symptomatic epilepsy due to an astrocytoma.
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for the remainder of the first month of treatment. He experienced only one seizure during the second month but developed acne vulgaris, dermal ablation and a furuncle which was interpreted as minocycline adverse effects. Minocycline was stopped which improved the skin eruptions but his epilepsy worsened again with daily clonic seizures of the left side. With re-introduction of dexamethasone 12 mg/d, the frequency of seizures dropped to a low level of one seizure every two weeks. Throughout the treatment period no change in the small tumor oedema, which could itself provoke seizures, was seen. In December 2010, the patient developed pulmonary and bone metastases of his melanoma and received palliative therapy. While the size of the astrocytoma remained stable, a new cerebral lesion was detected in July 2011 which was a probable metastasis of the melanoma. At last follow-up, he suffered still from one clonic seizure per day under zonisamide 300 mg/d, lamotrigine 300 mg/d and levetiracetam 4000 mg/d and dexamethasone 4 mg/d.
Discussion
The present case suggests that minocycline can have anticonvulsant properties in humans which may be due to its antiinflammatory mode of actions. 1 Minocycline is known to cross the blood-brain barrier (BBB). 5 In animal models of seizures, minocycline was shown to inhibit seizure susceptibility, hippocampal IL-1b levels, and glutamate receptor subunit expression, 6 and protect against hippocampal cell death induced by kainate acid treatment through inhibition of caspase-dependent and -independent pathways. 7 Peripheral injection of minocycline could reduce seizure susceptibility in rodents probably due to suppression of IL-1b release from microglia. 6 In addition, its ability to inhibit activated microglia may contribute to the anticonvulsant effects as experimental data showed that hippocampal neurogenesis was restored through inhibition of microglial activation in epileptic rats. 8 This adds further evidence to the impression that modulating immune processes can have anticonvulsant effects in human epilepsy 9 as already implied by the long-standing clinical experience that cortisone/ACTH has anticonvulsive effects in childhood and adult epilepsy including West syndrome and status epilepticus. 10 Based on this case report, we hypothesize that the effects of minocycline on IL-1b release and microglial activation can play a significant role in human epilepsy and that inhibiting these processes is anticonvulsive. However, it remains unclear whether tumor-induced epilepsy is especially or uniquely susceptible to immune modulating therapy as compared with other etiologies.
Further prospective studies are necessary to verify or falsify the hypothesis raised from this case report.
